Research Article

Predictive Role of F2-Isoprostanes as Biomarkers for Brain Damage after Neonatal Surgery

L. J. Stolwijk,1,2,3 P. M. A. Lemmers,1 M. Y. A. van Herwaarden,3 D. C. van der Zee,3 F. van Bel,1 F. Groenendaal,1 M. L. Tataranno,1,4 M. Calderisi,4 M. Longini,4 F. Bazzini,4 M. J. N. L. Benders,1,2 and G. Buonocore4

1Department of Neonatology, University Medical Center Utrecht, Utrecht, Netherlands
2Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, Netherlands
3Department of Pediatric Surgery, University Medical Center Utrecht, Utrecht, Netherlands
4Department of Pediatrics, Obstetrics and Reproductive Medicine, University of Siena, Siena, Italy

Correspondence should be addressed to M. J. N. L. Benders; m.benders@umcutrecht.nl

Received 5 May 2017; Revised 24 August 2017; Accepted 11 September 2017; Published 8 October 2017

Objective. Neonates have a high risk of oxidative stress during anesthetic procedures. The predictive role of oxidative stress biomarkers on the occurrence of brain injury in the perioperative period has not been reported before. Methods. A prospective cohort study of patients requiring major surgery in the neonatal period was conducted. Biomarker levels of nonprotein-bound iron (NPBI) in plasma and F2-isoprostane in plasma and urine before and after surgical intervention were determined. Brain injury was assessed using postoperative MRI. Results. In total, 61 neonates were included, median gestational age at 39 weeks (range 31–42) and weight at 3000 grams (1400–4400). Mild to moderate brain lesions were found in 66%. Logistic regression analysis showed a significant difference between plasma NPBI in patients with nonparenchymal injury versus no brain injury: 1.34 umol/L was identified as correlation threshold for nonparenchymal injury (sensitivity 67%, specificity 91%). In the multivariable analysis, correcting for GA, no other significant relation was found with the oxidative stress biomarkers and risk factors. Conclusion. Oxidative stress seems to occur during anaesthesia in this cohort of neonates. Plasma nonprotein-bound iron showed to be associated with nonparenchymal injury after surgery, with values of 1.34 umol/L or higher. Risk factors should be elucidated in a more homogeneous patient group.

1. Introduction

The impact of surgery and anaesthesia on the young infants’ brain is a subject of ongoing debate. Major surgery has been shown to give a higher risk of death or neurodevelopmental impairment in a large, retrospective cohort study in very low-birth-weight infants [1]. Commonly used inhalational anaesthetics are reported to be neurotoxic in experimental studies and induce neuronal apoptosis [2, 3]. Studies on the clinical effect of anaesthetics on the developing brain are challenging. Infants with major noncardiac congenital anomalies requiring neonatal surgery (esophageal atresia, intestinal atresia, anorectal malformation, and gastrochisis) have an increased risk of a neurodevelopmental delay [4]. These patients are at risk of oxidative stress due to the anaesthetic procedure including administration of sevoflurane, the fraction of inspired oxygen, and pain, especially since the tendency is to keep them highly saturated during surgery [5]. Fluctuations in blood pressure, arterial CO2, and duration of anaesthesia pose a risk for the neonatal brain in terms of developing brain injury [6]. In 63% of patients with noncardiac congenital anomalies in this cohort study, brain lesions were visible on their postoperative MRI [7]. The exact timing of the brain injury may help to discover the pathogenesis of these lesions. In this process, biomarkers of oxidative stress might provide insight into aetiology and pathogenic factors. To date, very few reported on the role of the anaesthetic procedure in this patient group. In this study, we hypothesize...
that biomarkers of oxidative stress (i.e., plasma and urinary F₂-isoprostane and plasma nonprotein-bound iron) are associated with brain injury and aim to clarify the aspects of oxidative stress during anaesthesia. The association between perioperative parameters, such as mean arterial blood pressure, arterial CO₂, administration of opioids and duration of anaesthesia, and biomarkers for neuronal injury, was investigated.

2. Material and Methods

2.1. Patients. This prospective, cohort study was performed from January 2014 to December 2015 at the Neonatal Intensive Care Unit of the Wilhelmina Children’s Hospital Utrecht, Utrecht, the Netherlands. All eligible newborns with noncardiac congenital anomalies, requiring major neonatal surgery, were enrolled. This study was approved by the Medical Ethical Committee of the University Medical Center Utrecht. Parents were asked for written informed consent, in accordance to the principles of the Declaration of Helsinki (64th WMA General Assembly, Fortaleza, Brazil, October 2013).

Exclusion criteria consisted of critical cardiac congenital malformations, major congenital anomalies of the central nervous system, and insufficient Dutch language proficiency of the parents.

3. Methods

3.1. Biomarkers. Heparinized blood samples of 1 ml were drawn from the indwelling peripheral arterial catheter and inserted for clinical purposes. These samples were centrifuged immediately, to obtain platelet-poor plasma, and butylated hydroxytoluene (BHT) 1% w/v in methanol (5 μl per ml of plasma) was added to prevent the in vitro lipid peroxidation [8]. Urine samples of 4 ml were collected from already inserted urinary catheters or noninvasively from a gauze placed in the infants’ diaper. Six time points were chosen: within 24 hours prior to surgery; immediately after surgery; and 6, 24, and 72 hours after surgery for measurement of biomarkers of neuronal injury (Figure 1). Blood and urine samples were stored in a refrigerator at −80°C until analysis. Plasma levels of NPBI were detected by high-performance liquid chromatography (HPLC) as described by Paffetti et al. [9] using an HPLC system consisted of quaternary pumps, vacuum degassers, thermostated autosampler, DAD detector, and fluorimeter detector (Agilent 1100 series). The method is based on preferential chelation of NPBI by a large excess of the low-affinity ligand of nitrilotriacetic acid (NTA).

Determination of F₂-isoprostanes in plasma and urine was described by Casetta et al. [10]. The method was centered around an API 4000 Tandem Mass Spectrometer (AB Sciex, Toronto, Canada) equipped with an electrospray ionization (ESI) probe on the Turbo-V source. The chromatographic configuration was an Agilent 1200 stack. The chromatographic configuration was an Agilent 1200 stack, which included a binary pump, a thermostated autosampler, DAD detector, and fluorimeter detector (Agilent 1100 series).

The method is based on preferential chelation of NPBI by a large excess of the low-affinity ligand of nitrilotriacetic acid (NTA).

Determination of F₂-isoprostanes in plasma and urine was described by Casetta et al. [10]. The method was centered around an API 4000 Tandem Mass Spectrometer (AB Sciex, Toronto, Canada) equipped with an electrospray ionization (ESI) probe on the Turbo-V source. The chromatographic configuration was an Agilent 1200 stack. The chromatographic configuration was an Agilent 1200 stack, which included a binary pump, a thermostated well-plate autosampler (kept at 8°C), and a column oven.

The chromatography separation was carried out on a Dionex Acclaim C18-120 3um 2×100 mm, maintained at 30°C, and flowed at a rate of 300 μl/min by a mixture of an aqueous solution of acetic acid at 0.3% (elucent A) and acetonitrile (elucent B) according to the following gradient program. Upon injection, the eluent composition was maintained at 25% of B for 1’ and then moves up to 90% in 4’. Subsequently, the concentration of eluent B reaches 100% for 1’. The equilibration step was performed at 25% of B for 4’. Total chromatographic run was 10 minutes.

For measurements, the tandem mass spectrometer has been run in multiple reaction monitoring (MRM) with the electrospray source operating in negative ion mode and by exploiting the transition m/z 353.3 > 193.2 for F₂-isoprostanes and 357.3 > 197.2 for the isotopically-labeled form used.
as internal standard (d4–8-iso PGF2α, Cayman Chemical Co., Ann Arbor, MI, USA) [11].

3.2. Neuroimaging. A postoperative MRI was performed on a 3.0 Tesla whole-body Achieva system (Philips Medical Systems, Best, the Netherlands) as part of routine clinical care. The scanning protocol included T1-, T2-, diffusion, and susceptibility weighted images.

3.3. Data. Obstetric and neonatal data, perioperative data, as well as details on anaesthetic and surgical management were collected from patient charts.

3.4. Statistical Analysis. Statistical procedures were performed using IBM SPSS statistics software package (IBM® SPSS Statistics version 20, IBM Corp. Armonk, NY, USA, and R statistical computing) [12]. Data are presented as mean ± standard deviation (SD) or as median and range when indicated. Comparison of biomarker levels before and after surgery was performed using the Wilcoxon signed-rank test and the Bonferroni post hoc correction for multiple testing. The Mann–Whitney U test was performed to compare biomarker levels and presence of brain injury. A multivariable regression analysis was performed using the cumulative concentration of biomarker levels in the first 60 hours after surgery. Parameters investigated were gender, type of congenital anomaly, endoscopic procedure, and the occurrence of parenchymal injury, after correcting for gestational age. Receiver operating characteristic curves (ROC) were calculated at different time points from T1 to T4, in order to detect the best time point correlating with damage.

4. Results

Of the 84 patients admitted to the NICU between January 2014 and December 2015 and who underwent major surgery in the neonatal period, parents of 73 neonates were approached and asked for consent of their infant to participate in the study. Exclusion criteria consisted of emergency surgery (n = 4), absence of one of the parents (n = 3), insufficient Dutch language proficiency (n = 3), or diagnosis made during surgery (n = 1). In 61 of these 73 neonates, parental informed consent was given. Clinical data are presented in Table 1 (Supplemental Table 1 available online at https://doi.org/10.1155/2017/2728103 and Supplemental Table 2. Anesthetics during surgery). Figure 1 shows the time distribution of each sampling point.

4.1. Oxidative Stress Biomarkers. Plasma and urinary levels of F2-isoprostane and plasma NPBI were not significantly different before surgery in comparison to values after surgery (T0 versus T1–T4, Wilcoxon signed-rank test with post hoc Bonferroni, p > 0.3) (Figure 2) (Supplemental Table 2).

4.2. Brain Lesions. Parenchymal and/or nonparenchymal brain lesions were found in 66% of 58 postoperative MRI scans (Table 2 and Figure 3). In 18 neonates, a combination of parenchymal and nonparenchymal injury was visible. In 51% of the neonates, parenchymal injury was present and 55% of these lesions were visible on the diffusion weighted images (DWI), which indicates timing of the injury to be in the perioperative period. The cumulative concentration of plasma F2-isoprostane of patients with no brain injury showed significantly lower levels than patients with parenchymal injury (Mann–Whitney U test, U = 11.0, p < 0.01, r = −0.70, Figure 4), indicating higher concentrations of F2-isoprostane in patients with brain injury.

4.3. Multivariable Linear Regression. In the multivariable analysis, using the cumulative concentration starting directly after surgery to 60 hours after surgery for each biomarker, correcting for GA, none of the potentially influencing factors showed a significant linear relation with plasma and urinary F2-isoprostane or plasma NPBI. Parameters investigated consisted of gender, type of congenital anomaly, endoscopic procedure, and the occurrence of parenchymal injury (Figure 4). This indicates that after correcting for gestational age, the absence or presence of brain injury did not influence the overall concentrations of the oxidative stress biomarkers in the perioperative period.

4.4. ROC Curve Analysis. A logistic regression was performed for each time point. A significant difference in plasma NPBI was found between patients with nonparenchymal injury

| Table 1: Clinical data. |
|-------------------------|------------------|
|                         | n = 61           |
| Gestational age (weeks) | 38.9 (30.9–41.6) |
| Male, n (%)             | 36 (59%)         |
| Birth weight (grams)    | 3000 (1405–4430) |
| Birth weight z-score    | −0.25 (−2.1–1.9) |
| Small for gestational age, n (%) | 2 (3%) |
| Preterm, n (%)          | 15 (25%)         |
| Apgar score 1 minute    | 9 (2–10)         |
| Apgar score 5 minutes   | 10 (2–10)        |
| Postnatal age in days at time of surgery | 2 (0–8) |
| Postnatal age in hours at time of surgery | 39.9 (2–184) |
| Surgery                 |                  |
| Thoracoscopy, n (%)     | 18 (30%)         |
| Laparotomy, n (%)       | 23 (38%)         |
| Duration surgery (minutes) | 115 (23–475) |
| Duration anaesthesia (minutes) | 189 (63–563) |
| Medication during anaesthesia |           |
| Sevoflurane, n (%)      | 60 (98%)         |
| Isoflurane, n (%)       | 1 (2%)           |
| Sufentanil, n (%)       | 60 (98%)         |
| Propofol, n (%)         | 14 (23%)         |
| Morphine, n (%)         | 17 (28%)         |
| Caudal analgesia, n (%) | 13 (21%)         |
| Suxamethonium, n (%)    | 1 (2%)           |
| Atracurium, n (%)       | 51 (84%)         |
| Rocuronium, n (%)       | 9 (15%)          |

Data displayed in median (range) or indicated otherwise.
Figure 2: Perioperative data of oxidative stress biomarkers. (a) Data of plasma NPBI at each time point. Dotted line indicates 2.3 umol/L NPBI, and normal values of plasma NPBI are below this cutoff value. (b) Data of plasma F2-isoprostane at each time point. Dotted line indicates 60 pg/mL F2-isoprostane, and normal values of plasma F2-isoprostane are below this cutoff value. (c) Data of urinary F2-isoprostane at each time point. Dotted line indicates 1.3 pg/mg creatinine F2-isoprostane, and normal values of urinary F2-isoprostane are below this cutoff value.
The basal level of oxidative stress before surgery was reported values after surgery in comparison to preoperative values.

Table 2: Incidence of brain injury.

| Brain injury                        | n*   |
|-------------------------------------|------|
| No injury                           | 20   |
| Parenchymal injury                  | 13   |
| Nonparenchymal injury               | 7    |
| Parenchymal and nonparenchymal injury | 18  |

*MRI was not available in three patients: one was declined by the parents, one had a preoperative MRI scan only, and one patient was diagnosed with Down’s syndrome.

(78.5%) and patients with no brain injury after anaesthesia. The results indicate plasma NPBI at 72 hours after surgery as the best early predictor for nonparenchymal injury. The determination of NPBI levels at 72 hours after surgery allows in differentiating neonates having nonparenchymal brain injury from no brain injury: AUC 78.5% (95% confidence interval: 0.595–0.975), with 66.7% specificity and 90.9% sensitivity (Figure 5). The threshold 1.34 μM/L was identified as predictive value for having nonparenchymal injury. A predictive threshold value at one specific time point could not be identified for F₂-isoprostan.

5. Discussion

This study investigated oxidative stress biomarkers in neonates undergoing neonatal surgery for noncardiac congenital anomalies. In this cohort, 66% of the neonates had mild to moderate brain lesions visible on their postoperative MRI. A combination of parenchymal and nonparenchymal injury was found in 30% of the infants. In the total patient cohort, after correcting for gestational age, perioperative biomarker concentrations of F₂-isoprostan and NPBI were not correlated to perioperative brain injury. In the ROC curve analysis, assessing the subgroups no brain injury, parenchymal and nonparenchymal brain injury at each time point, and oxidative stress seems to occur as a consequence of anaesthesia. This was shown by elevated levels of NPBI in plasma and urinary F₂-isoprostan after surgery in patients with parenchymal injury in comparison to patients with no brain injury. In addition to that, the level of 1.34 μmol/L plasma NPBI was identified as risk threshold for nonparenchymal injury. Despite the bias related to heterogeneity, this study points out that these neonates are at risk of oxidative stress during the anaesthetic procedure.

There is no previous literature available on biomarkers in patients with noncardiac congenital anomalies requiring surgery. This could be explained by the fact that patients with congenital malformations are structurally excluded from trials. However, biomarkers of neuronal injury might be of great value in this vulnerable group of patients.

The hypothesis was to find an increase in biomarker values after surgery in comparison to preoperative values. The basal level of oxidative stress before surgery was reported for the first time. Interestingly, the values of F₂-isoprostan at baseline—before surgery—were low, in comparison to the findings of Comporti et al. Newborns in this study had values between 50–150 pg/ml after birth, and blood samples were obtained from the umbilical vein. Our results show a median F₂-isoprostan of 30 pg/ml creatinine at baseline, which is drawn from the arterial catheter at a median age of two days. Apparently, the oxidative stress at birth caused by the transition from a low oxygen pressure in utero to a relatively high oxygen pressure after birth was resolved [19].

Oxidative stress is a unifying term for the end product of several diseases, which can be produced by free radicals. Biomarkers are defined as indicators of normal processes or measures of pathological processes [13]. Free radicals damage the endothelial cell and cause inflammatory reactions and brain cell damage, which can be evaluated by an increased level of nonprotein-bound iron. NPBI has been proven to be a predictive biomarker of neonatal brain damage in preterm infants [14]. This biomarker seems to play a pivotal role in identifying neonates at risk of brain damage. F₂-isoprostanes, discovered by Morrow et al, are a product of free radical-induced injury by peroxidation of lipids. This biomarker is formed via nonenzymatic peroxidation of polyunsaturated fatty acids mediated by free radical production [13]. This peroxidation of arachidonic acid is produced by a noncyclooxygenase mechanism [15] and is a noninvasive method to monitor lipid peroxidation in vivo. An increase of F₂-isoprostan in plasma and urine occurs after hypoxic-ischaemic brain injury and reperfusion [16] and predicts the risk of having brain injury. Previous studies have shown that F₂-isoprostan is a reliable and chemically stable biomarker [17, 18]. Importantly, it is previously described that plasma F₂-isoprostan levels are inversely correlated with gestational age [19]. This is also the case in healthy infants, Friel et al. found an increased level of F₂-isoprostan in a cohort of 12 infants at the age of one month [5]. Furthermore, lipid exposure to high concentrations of NPBI also leads to the formation of isoprostanes.

Reactive oxygen species (ROS) are known to cause oxidative stress in the newborn infant, leading to damage to cell structures like lipids and membranes [5, 20, 21]. Free radical oxidative damage in the newborn is involved in diseases like retinopathy of prematurity, bronchopulmonary dysplasia, necrotizing enterocolitis, and patent ductus arteriosus [21]. In addition, the developing brain of the neonate, with its high concentration of polyunsaturated fatty acids, is highly susceptible to hypoxia and hyperxia [22]. These pathological circumstances cause oxidative stress reactions, in particular in the neonate with their immature antioxidant defenses [23]. White matter is selectively injured, since the developing oligodendrocyte is the main target of oxidative stress in hypoxia-ischaemia and systemic inflammation [22, 24]. Brain injury has previously been described in the group of patients with cardiac congenital anomalies undergoing major surgery [25]. Our results show a high incidence of mild to moderate brain lesions in infants with noncardiac congenital anomalies as well.

The sensitivity of the rapidly developing brain of the neonate undergoing major surgery to brain injury is threefold. First, the developing brain tissue is sensitive to free radicals. ROS cause oxidative stress [20], in particular, in newborns with their reduced enzymatic and nonenzymatic antioxidant defense [21]. Neonates undergoing surgery are exposed to
Figure 3: Examples of parenchymal and nonparenchymal brain injury. (a) Coronal T1-weighted image: cortical infarction and subdural haemorrhage; (b) coronal T1-weighted image: white matter lesion; (c) coronal T1-weighted image: white matter lesion; (d) susceptibility weighted image: multiple punctate cerebellar lesions; (e) diffusion-weighted image: thalamic infarction; (f) susceptibility weighted image: cerebellar haemorrhage.
fluctuating fractions of inspired oxygen. During induction of anaesthesia, an increased supply of oxygen is administered, to prevent hypoxia during intubation, which enhances the risk of free oxygen radicals. Secondly, inhalational anaesthetics are thought to cause neurotoxic effects in the developing newborn brain [2, 26, 27]. The anaesthetic causes an increase in apoptosis, an impaired neurogenesis, and neuroinflammation in animal experimental studies [28]. Third, cerebral perfusion is at risk due to immature cerebral autoregulatory ability in preterm infants or a loss of cerebral autoregulation caused by sevoflurane anaesthesia [29]. Presence or absence of autoregulatory ability can be determined by blood pressure and cerebral oxygenation, measured by near-infrared spectroscopy [30]. In case of pressure-passive perfusion, fluctuations in respiratory and cardiovascular parameters pose a risk for cerebral saturation and perfusion. Maintenance of cerebral blood flow is critical to ensure adequate oxygenation of the brain.

This study has several limitations. First, with the use of F₂-isoprostane only, a specific type of brain damage was investigated, involving the prostaglandin metabolism. The second limitation is that our cohort consists of a heterogeneous patient group. In order to solve this problem, each patient is used as their own control, with the baseline measurement before surgery. Furthermore, the bias consisted of differences in gestational age, weight, different surgical techniques, and differences in administered dose of anaesthesia and pain medication. The strength of this study, however, is that it is the first study to investigate these biomarkers in neonates with noncardiac congenital anomalies, at multiple time points, in combination with the use of MRI. Also, the clinical use of these biomarkers is investigated in this prospective study where cerebral monitoring is applied in the perioperative period as well. The combination of biomarkers and MRI offers the opportunity to identify neonates at risk of brain injury more precisely, which might be of great value to develop tailored therapy and preventive measures for brain injury in the future.

6. Conclusion

Despite the bias related to heterogeneity of the study group, our results showed a risk of oxidative stress during anaesthesia in neonates.


**Abbreviations**

NCCA: Noncardiac congenital anomalies  
NPBI: Nonprotein bound iron  
NICU: Neonatal intensive care unit  
NIRS: Near-infrared spectroscopy  
GA: Gestational age.

**Disclosure**

M. J. N. L. Benders and G. Buonocore are shared last authors.

**Conflicts of Interest**

The authors declare that there is no conflict of interest regarding the publication of this article.

**Acknowledgments**

L. J. Stolwijk is supported by the NUTS OHRA foundation grant and received the Young Investigator Start-Up Grant of the European Society of Paediatric Research. No other sources of support were used.

**References**

[1] F. H. Morriss, S. Saha, E. F. Bell et al., “Surgery and neurodevelopmental outcome of very low-birth-weight infants,” JAMA Pediatrics, vol. 168, pp. 746–754, 2014.

[2] B. Sinner, K. Becke, and K. Engelhard, "General anaesthetics and the developing brain: an overview," Anaesthesia, vol. 69, pp. 1009–1022, 2014.

[3] L. Sun, "Early childhood general anaesthesia exposure and neurocognitive development," British Journal of Anaesthesia, vol. 105, Supplement 1, pp. i61–i68, 2010.

[4] L. J. Stolwijk, P. M. Lemmers, M. Harmsen et al., "Neurodevelopmental outcomes after neonatal surgery for major noncardiac anomalies," Pediatrics, vol. 137, article e20151728, 2014.

[5] J. K. Friel, R. W. Friesen, S. V. Harding, and L. J. Roberts, "Evidence of oxidative stress in full-term healthy infants," Pediatric Research, vol. 56, pp. 878–882, 2004.

[6] M. E. McCann, A. N. Schouten, N. Dobija et al., "Infantile postoperative encephalopathy: perioperative factors as a cause for concern," Pediatrics, vol. 133, pp. e751–e757, 2014.

[7] L. J. Stolwijk, K. Keunen, L. S. de Vries et al., "Neonatal surgery for noncardiac congenital anomalies: neonates at risk of brain injury," The Journal of Pediatrics, vol. 182, pp. 335–341.e1, 2017.

[8] G. L. Milne, Q. Dai, and L. J. Roberts, "The isoprostanes—25 years later," Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, vol. 2015, pp. 433–445, 2015.

[9] P. Paffetti, S. Perrone, M. Longini et al., "Non-protein-bound iron detection in small samples of biological fluids and tissues," Biological Trace Element Research, vol. 112, pp. 221–232, 2006.

[10] B. Casetta, M. Longini, F. Proietti, S. Perrone, and G. Buonocore, “Development of a fast and simple LC-MS/MS method for measuring the F2-isoprostanes in newborns,” The Journal of Maternal-Fetal & Neonatal Medicine, vol. 25, Supplement 1, pp. 114–118, 2012.

[11] M. Longini, S. Giglio, S. Perrone et al., “Proton nuclear magnetic resonance spectroscopy of urine samples in preterm asphyctic newborn: a metabolomic approach,” Clinica Chimica Acta, vol. 444, pp. 250–256, 2015.

[12] R. Core Team, "R: A language and environment for statistical computing," in R Foundation for Statistical Computing, Austria, Vienna, 2014, http://www.R-project.org/.

[13] E. Miller, A. Morel, L. Saso, and J. Saluk, "Isoprostanes and neuroprostanes as biomarkers of oxidative stress in neurodegenerative diseases," Oxidative Medicine and Cellular Longevity, vol. 2014, Article ID 572491, 10 pages, 2014.

[14] G. Buonocore, S. Perrone, M. Longini et al., "Non protein bound iron as early predictive marker of neonatal brain damage," Brain, vol. 126, pp. 1224–1230, 2003.

[15] J. D. Morrow, K. E. Hill, R. F. Burk, T. M. Nammour, K. F. Badr, and L. J. Roberts, “A series of prostaglandin F2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical-catalyzed mechanism,” Proceedings of the National Academy of Sciences of the United States of America, vol. 87, pp. 9383–9387, 1990.

[16] G. L. Milne, E. S. Musiek, and J. D. Morrow, “F2-isoprostanes as markers of oxidative stress in vivo: an overview,” Biomarkers, vol. 10, Supplement 1, pp. S10–S23, 2005.

[17] G. L. Milne, H. Yin, K. D. Hardy, S. S. Davies, and L. J. Roberts, “Isoprostane generation and function,” Chemical Reviews, vol. 111, pp. 5973–5996, 2011.

[18] M. L. Tataranno, S. Perrone, and G. Buonocore, “Plasma biomarkers of oxidative stress in neonatal brain injury,” Clinics in Perinatology, vol. 42, pp. 529–539, 2015.

[19] M. Comporti, C. Signorini, S. Leoncini, G. Buonocore, V. Rossi, and L. Ciccoli, “Plasma F2-isoprostanes are elevated in newborns and inversely correlated to gestational age,” Free Radical Biology & Medicine, vol. 37, pp. 724–732, 2004.

[20] M. Valko, D. Leibfritz, J. Moncol, M. Mazur, and J. Telser, “Free radicals and antioxidants in normal physiological functions and human disease,” The International Journal of Biochemistry & Cell Biology, vol. 39, pp. 44–84, 2007.

[21] O. D. Saugstad, “Oxidative stress in the newborn – a 30-year perspective,” Biology of the Neonate, vol. 88, pp. 228–236, 2005.

[22] J. J. Volpe, H. C. Kinney, F. E. Jensen, and P. A. Rosenberg, "The developing oligodendrocyte: key cellular target in brain injury in the premature infant," International Journal of Developmental Neuroscience, vol. 29, pp. 423–440, 2011.

[23] A. A. Baburamani, C. J. Ek, D. W. Walker, and M. Castillo-Melendez, "Vulnerability of the developing brain to hypoxic-ischemic damage: contribution of the cerebral vasculature to injury and repair?," Frontiers in Physiology, vol. 3, p. 424, 2012.

[24] D. M. Ferriero, “Neonatal brain injury,” The New England Journal of Medicine, vol. 351, pp. 1983–1995, 2004.

[25] S. O. Algra, N. J. Jansen, I. van der Tweel et al., "Neurological injury after neonatal cardiac surgery: a randomized, controlled trial of 2 perfusion techniques," Circulation, vol. 129, pp. 224–233, 2014.

[26] B. A. Rappaport, S. Suresh, S. Hertz, A. S. Evers, and B. A. Orser, “Anesthetic neurotoxicity — clinical implications of animal models,” The New England Journal of Medicine, vol. 372, pp. 796–797, 2015.

[27] A. J. Davidson, “Anesthesia and neurotoxicity to the developing brain: the clinical relevance,” Paediatric Anaesthesia, vol. 21, pp. 716–721, 2011.
[28] R. D. Sanders, J. Hassell, A. J. Davidson, N. J. Robertson, and D. Ma, “Impact of anaesthetics and surgery on neurodevelopment: an update,” *British Journal of Anaesthesia*, vol. 110, Supplement 1, pp. i53–i72, 2013.

[29] O. Rhondali, A. Mahr, S. Simonin-Lansiaux et al., “Impact of sevoflurane anesthesia on cerebral blood flow in children younger than 2 years,” *Paediatric Anaesthesia*, vol. 23, pp. 946–951, 2013.

[30] A. Caicedo, S. D. De, G. Naulaers et al., “Cerebral tissue oxygenation and regional oxygen saturation can be used to study cerebral autoregulation in prematurely born infants,” *Pediatric Research*, vol. 69, pp. 548–553, 2011.